Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Anthony Stein
MSR120 DEVELOPMENT OF A NOVEL ALGORITHM TO IDENTIFY CAPILLARY LEAK SYNDROME (CLS) IN US CLAIMS DATA
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial
Get full text access Log in, subscribe or purchase for full access. References 1. Gökbuget, N ∙ Stanze, D ∙ Beck, J ∙ et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation Blood. 2012; 120:2032-2041 2. Breems, DA ∙ Van Putten, WL ∙ Huijgens, PC ∙ et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse J Clin Oncol. 2005; 23:1969-1978 3.
Treatment of Relapsed/Refractory AML—Novel Treatment Options Including Immunotherapy
1 Introduction The past decade has seen tremendous progress in our understanding of the genetic and epigenetic heterogeneity underlying the pathogenesis of acute myeloid leukemia (AML).
[2412.00256] Excretion Detection in Pigsties Using Convolutional and Transformerbased Deep Neural Networks
Thank you to everyone who makes arXiv possible. Give to arXiv today and help keep science open.
Pansharpening Low-Altitude Multispectral Images of Potato Plants Using a Generative Adversarial Network
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia
DISCUSSION Our study represents one of the largest analyses of the impact of leukemia burden on the efficacy and safety of blinatumomab. Pooling data from five clinical trials allowed us to analyze a large, comprehensively annotated cohort of blinatumomab-treated patients, thereby increasing the robustness, representativeness, and reliability of the findings.
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju Employment: MD Anderson Cancer Center Leadership: ASH, ASCO Honoraria: Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, AbbVie, MustangBio, Roche Molecular Diagnostics, Blueprint Medicines, DAVA Pharmaceuticals, Springer, Aptitude Health, NeoPharm, CareDX Consulting or Advisory Role: Blueprint Medicines, Pacylex, Immunogen, Bristol Myers Squibb, ClearView Healthcare Partners, Astellas Pharma, Protagonist Therapeutics, Triptych Health Partners, CTI...
3D Printing Finance: Plotting a Bright Future
Home / Articles / Read Article Recipient's Email Address(es) (Separate multiple addresses with a comma) Your Email Address Send a copy to myself Your Message (optional) 3D Printing Finance: Plotting a Bright Future Date: Oct 18, 2016 @ 07:00 AM The printing industry is experiencing substantial innovation, especially in the area of 3D printing, also known as additive manufacturing or scalable digital manufacturing (SDM).
Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
Original Article Gerhard Zugmaier MD, PhD Corresponding Author E-mail address: gerhardz@amgen.com Amgen GmbH, Munich, Germany Corresponding Author: Gerhard Zugmaier, MD, PhD, Amgen GmbH, Munich, Germany (E-mail address: gerhardz@amgen.com). Search for more papers by this author Abstract Background Blinatumomab is a CD19 BiTE (bispecific T‐cell engager) immuno‐oncology therapy that mediates the lysis of cells expressing CD19.
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Intensive induction chemotherapy followed by consolidation chemotherapy and/or allogeneic hematopoietic stem cell transplantation (HSCT) with curative intent is standard of care for younger, medically fit patients with newly diagnosed (ND) acute myeloid leukemia (AML). However, intensive chemotherapy (IC) regimens are often unsuitable for older patients or individuals with comorbidities.
3D Printing Finance: Plotting a Bright Future
Hi, I thought you would be interested in this article from Equipment Finance Advisor. The printing industry is experiencing substantial innovation, especially in the area of 3D printing, also known as additive manufacturing or scalable digital manufacturing (SDM). Historically, most 3D printer users have been large manufacturers and educational institutions since the cost and space needed to use these printers was generally prohibitive for small businesses and consumers.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Anthony
Contact Anthony, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack